Ipamorelin vs Sermorelin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: IPAM, NNC 26-0161
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk and derived from GHRP-1. It is researched mainly for stimulating the body's own growth hormone (GH) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. It is not an approved drug anywhere: it reached Phase II trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical.
Also: Geref, GRF 1-29
Sermorelin is a 29-amino-acid fragment of human growth hormone-releasing hormone (GHRH), and it is the shortest piece of GHRH that still works fully. It asks the pituitary to make and release its own growth hormone rather than injecting GH itself. It was once an FDA-approved drug for diagnosing and treating growth hormone deficiency in children, but the manufacturer pulled it from the market in 2008, so today it is available mainly through compounding pharmacies for off-label use.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Ipamorelin has stronger research evidence (Human Trials) compared to Sermorelin (Animal Studies).
Detailed Comparison
| Attribute | Ipamorelin | Sermorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Ipamorelin is an agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a) on the somatotroph cells of the anterior pituitary. Binding this receptor triggers intracellular signaling (Gq/phospholipase C, IP3 and calcium release) that makes the pituitary release stored GH in pulses, mimicking natural ghrelin. Its defining feature, established in the original 1998 characterization, is selectivity: at GH-releasing doses it does not meaningfully raise ACTH, cortisol, prolactin, FSH, LH or TSH, making it cleaner than older peptides like GHRP-2 and GHRP-6. Because it works on the pituitary's own GH reserves, the effect depends on a functioning pituitary and natural feedback loops stay in place. | Sermorelin copies the first 29 amino acids of natural GHRH and binds the GHRH receptor on the anterior pituitary, which is the body's normal on-switch for growth hormone production. Activating that receptor tells the pituitary to synthesize and release GH in pulses. A useful safety feature falls out of this design: because the pituitary still answers to its own inhibitory hormone somatostatin, the GH rise stays under negative-feedback control, which makes a true overdose of GH much harder to produce than with injected recombinant GH. |
| Common Dosing | 200-300 mcg 2-3x daily 2-3x daily | 200-500 mcg before bed Once daily, typically before bed |
| Administration | Subcutaneous injection | Subcutaneous injection at bedtime |
| Typical Duration | 8-12 weeks typical | 3-6 months typical |
| Best Time to Take | Before bed or morning (fasted) | Before bed (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The foundational work is Raun et al. (1998) in the European Journal of Endocrinology, which characterized ipamorelin in rats, pigs and isolated pituitary cells and named it the first selective growth hormone secretagogue, releasing GH without raising ACTH or cortisol even at doses far above the GH-releasing dose. Most rigorous data is preclinical. In humans, the compound was advanced into Phase II trials for postoperative ileus but was discontinued for insufficient efficacy. There are no large peer-reviewed human randomized controlled trials supporting the popular anti-aging, fat-loss, muscle-gain or recovery claims; those uses are extrapolations from the mechanism, not proven outcomes. Honestly stated: the receptor mechanism and GH-release effect are well documented, but human efficacy and long-term safety for wellness use are not established. | Sermorelin has a real clinical pedigree, unlike many gray-market peptides. The FDA approved it in 1990 as a diagnostic for GH deficiency and in 1997 for treating idiopathic GH deficiency in children with growth failure, after studies showed about six months of daily injections increased GH release and growth velocity. Published work found intravenous sermorelin is a relatively specific test for GH deficiency with few false positives, and once-daily subcutaneous dosing promoted growth in some GH-deficient prepubertal children. Where the evidence gets thin is the popular adult anti-aging use: a 2006 editorial argued sermorelin is a smarter way to address age-related GH decline than recombinant GH, but it openly conceded that few long-term clinical studies exist. The drug was discontinued commercially in 2008 for business reasons, not safety, so current adult use rests on compounded product and limited modern trial data. |
Frequently Asked Questions: Ipamorelin vs Sermorelin
What is the difference between Ipamorelin and Sermorelin?
Ipamorelin is a growth hormone peptide that ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by novo nordisk and derived from ghrp-1. it is researched mainly for stimulating the body's own growth hormone (gh) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. it is not an approved drug anywhere: it reached phase ii trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical. Sermorelin is a growth hormone peptide that sermorelin is a 29-amino-acid fragment of human growth hormone-releasing hormone (ghrh), and it is the shortest piece of ghrh that still works fully. it asks the pituitary to make and release its own growth hormone rather than injecting gh itself. it was once an fda-approved drug for diagnosing and treating growth hormone deficiency in children, but the manufacturer pulled it from the market in 2008, so today it is available mainly through compounding pharmacies for off-label use. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Ipamorelin or Sermorelin?
Neither is universally "better" - the choice depends on your specific goals. Ipamorelin is typically used for growth hormone purposes, while Sermorelin is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Ipamorelin and Sermorelin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Ipamorelin and Sermorelin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.